Report Library
All Reports
NHL: Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview - US, Northeast
June 27, 2024
A German-based KOL gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Topics discussed include the approval of CAR-T therapy for second-line patients, as well as trials evaluating T-cell-directed bispecific antibodies for the first- and second-line settings.
This interview was conducted on 28 May 2024.
If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.
Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: | Diffuse Large B-Cell Lymphoma (DLBCL) - NHL |
Additional Resources: